Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34+ stem cell-derived NK cell therapy after hepatectomy for hepatocellular carcinoma
jRCTb060200020Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of CD34+ stem cell-derived natural killer cells and filgrastim in hepatocellular carcinoma (HCC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety evaluation after NK cell immunotherapy. Started Oct 2021; status: recruiting.
02
Drugs
CD34+ stem cell-derived natural killer cellsfilgrastim
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTb060200020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb060200020.